

BC Cancer ST Program Updates for April, 2022

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version
 - **Do not** use the Copy Forward functionality to ensure that the updates apply



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning)

Please see this month's changes below.

PowerPlan: LYIT

Cycles/PowerPlans: LYIT (Weekly Option), LYIT (Twice Weekly Option), LYIT (Single Dose Option)

Changes:

The PowerPlan and Regimen names has been updated for Weekly and Twice Weekly options.

- The original LYIT PowerPlan and Regimen are renamed with Twice Weekly Option
- New PowerPlan and Regimen are created for the Weekly Option

	ONC LY LYIT (Twice Weekly Option)
	ONC LY LYIT (Weekly Option)
	ONCP LY LYIT (Single Dose Option)
	ONCP LY LYIT (Twice Weekly Option)
	ONCP LY LYIT (Weekly Option)
	ONCP LY LYIT Pretreatment Plan

In the Chemotherapy phase of all PowerPlans, the yellow note was added for “Refer to local guidelines for anticoagulation management”

Treatment Regimen	
	Refer to local guidelines for anticoagulation management
<input checked="" type="checkbox"/>	Zero Time
<input checked="" type="checkbox"/>	methotrexate (methotrexate - oncology) 12 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only. Days 1, 8, 15
<input checked="" type="checkbox"/>	cytarabine (cytarabine - oncology) 50 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only. Days 4, 11, 18

In the Chemotherapy phase of LYIT (Weekly Option), methotrexate (Days 1, 15, 29) and cytarabine (Days 8, 22, 36) are to be administered weekly

Component	Day 1	Day 8	Day 15	Day 22	Day 29	Day 36
Treatment Regimen	Future Pending *Est. 16-Mar-2022 08:...	Future Pending *Est. 23-Mar-2022 08:...	Future Pending *Est. 30-Mar-2022 08:...	Future Pending *Est. 06-Apr-2022 08:...	Future Pending *Est. 13-Apr-2022 08:...	Future Pending *Est. 20-Apr-2022 08:...
Refer to local guidelines for anticoagulation management	Actions	Actions	Actions	Actions	Actions	Actions
<input checked="" type="checkbox"/> Zero Time	Planned 0 hr	Planned 0 hr	Planned 0 hr	Planned 0 hr	Planned 0 hr	Planned 0 hr
<input checked="" type="checkbox"/> methotrexate (methotrexate - oncology) 12 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only. Days 1, 15, 29	Planned 0 min		Planned 0 min		Planned 0 min	
<input checked="" type="checkbox"/> cytarabine (cytarabine - oncology) 50 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only. Days 8, 22, 36		Planned 0 min		Planned 0 min		Planned 0 min

In the Labs phase of LYIT (Weekly Option), all lab orders are ordered prior to each days of treatment (Days 8, 15, 22, 29, 36, 43)

Component	Day 8	Day 15	Day 22	Day 29	Day 36	Day 43
ONCP LY LYIT (Weekly Option) - Cycle 1, Labs (Day 8, 15, 22, 29, 36, 43) (Future Pending) *Est. 22-Mar-2022 08:00 PDT - 42 Days	Future Pending *Est. 22-Mar-2022 08:...	Future Pending *Est. 29-Mar-2022 08:...	Future Pending *Est. 05-Apr-2022 08:...	Future Pending *Est. 12-Apr-2022 08:...	Future Pending *Est. 19-Apr-2022 08:...	Future Pending *Est. 26-Apr-2022 08:...
CBC and Differential Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned
PTT Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned
INR Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned

In the Scheduling phase of LYIT (Weekly Option), all scheduling orders are ordered for each days treatment (Days 1, 8, 15, 22, 29, 36)

ONCP LY LYIT (Weekly Option) - Cycle 1, Scheduling (Initiated Pending)		
For ambulatory clinic administration, select the orders below:		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Intrathecal Chemotherapy Visit	Within 2 Weeks Day 1
<input type="checkbox"/>	<input checked="" type="checkbox"/> Intrathecal Chemotherapy Visit	Within 2 Weeks Day 8
<input type="checkbox"/>	<input checked="" type="checkbox"/> Intrathecal Chemotherapy Visit	Within 2 Weeks Day 15
<input type="checkbox"/>	<input checked="" type="checkbox"/> Intrathecal Chemotherapy Visit	Within 2 Weeks Day 22
<input type="checkbox"/>	<input checked="" type="checkbox"/> Intrathecal Chemotherapy Visit	Within 2 Weeks Day 29
<input type="checkbox"/>	<input checked="" type="checkbox"/> Intrathecal Chemotherapy Visit	Within 2 Weeks Day 36
For Interventional Radiology administration, select the orders below:		
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Order for future visit Day 1
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Order for future visit Day 8
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Order for future visit Day 15
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Order for future visit Day 22
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Order for future visit Day 29
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Order for future visit Day 36
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Follow Up - Clinic - Oncology On Treatment	Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma

In the Chemotherapy phase for LYIT (Twice Weekly Option), Pre-Chemo Metrics have been separated between Days 1, 8, 15 and Days 4, 11, 18.

Pre-Chemo Metrics	
May proceed with treatment on Day 1, Day 8, and Day 15 if:	
<input checked="" type="checkbox"/>	Neutrophils Greater Than or Equal to $0.5 \times 10^9/L$ within 24 hours
<input checked="" type="checkbox"/>	Platelet Count Greater Than or Equal to $50 \times 10^9/L$ within 24 hours
<input checked="" type="checkbox"/>	INR Less Than 1.5 within 24 hours
<input checked="" type="checkbox"/>	PTT Less Than or Equal to ULN within 24 hours
May proceed with treatment on Day 4, Day 11, and Day 18 if:	
<input checked="" type="checkbox"/>	Platelet Count Greater Than or Equal to $50 \times 10^9/L$ within 24 hours
<input checked="" type="checkbox"/>	INR Less Than 1.5 within 24 hours
<input checked="" type="checkbox"/>	PTT Less Than or Equal to ULN within 24 hours

In the Labs phase of LYIT (Twice Weekly Option), all lab orders are ordered prior to each days of treatment (Day 4, 8, 11, 15, 18, 22)

ONCP LY LYIT (Twice Weekly Option) - Cycle 1, Labs (Day 4, 8, 11, 15, 18, 22) (Future Pending) *Est. 18-Mar-2022 08:00 PDT - 21 Days							
Component	Day 4	Day 8	Day 11	Day 15	Day 18	Day 22	
	Future Pending *Est. 18-Mar-2022 08:00...	Future Pending *Est. 22-Mar-2022 08:00...	Future Pending *Est. 25-Mar-2022 08:00...	Future Pending *Est. 29-Mar-2022 08:00...	Future Pending *Est. 01-Apr-2022 08:00...	Future Pending *Est. 05-Apr-2022 08:00...	
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned	
<input checked="" type="checkbox"/> PTT Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned	
<input checked="" type="checkbox"/> INR Blood, once, Order for future visit	Planned	Planned	Planned	Planned	Planned	Planned	

Versioning: Y

Jira: CST-161171



PowerPlan: LYVIPDRT

Cycles/PowerPlans: LYVIPDRT cycles 2 to 4

Changes:

Added a mesna prescription in the Prescriptions phase





ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2, Prescriptions (Future Pending)

<input checked="" type="checkbox"/>	 dexamethasone	40 mg, PO, as directed, Take daily on days 1-4 of each cycle, drug form: tab, dispense qty: 21 day Prescription is part of a combined IV/PO protocol. Dispense quantity = 1 cycle
<input checked="" type="checkbox"/>	 mesna	480 mg/m ² , PO, as directed, 4 and 8 hours after ifosfamide infusion on days 1 to 3. To be taken at home in 1 cup Round dose to nearest 10 mg. Prescription is part of a combined IV/PO protocol. Pharmacy to prepare 2 doses d

mesna
Details:
480 mg/m², PO, as directed, 4 and 8 hours after ifosfamide infusion on days 1 to 3. To be taken at home in 1 cup of carbonated beverage over 15 minutes, drug form: syringe-oral, dispense qty: 21 day
Order Comment:
Round dose to nearest 10 mg. Prescription is part of a combined IV/PO protocol. Pharmacy to prepare 2 doses daily for outpatient use. Dispense quantity = 1 cycle

Added 3 mesna orders in the Prescriptions (Inpatient Use Only) phase for the 3 days of treatment

ONCP LY LYVIPDRT Cycles 2 to 4 - Cycle 2, Prescriptions (Inpatient Use Only) (Future Pending)

<input type="checkbox"/>	 dexamethasone	40 mg, PO, qdaily with breakfast, order duration: 4 doses or times, drug form: tab Medication is part of a combined IV/PO protocol. Days 1 to 4
<input type="checkbox"/>	 mesna	480 mg/m ² , PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T;N+420 4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/P...
<input type="checkbox"/>	 mesna	480 mg/m ² , PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T+1;N+420 4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/P...
<input type="checkbox"/>	 mesna	480 mg/m ² , PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T+2;N+420 4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/P...

mesna
Details:
480 mg/m², PO, q4h oncology, order duration: 2 doses or times, drug form: syringe-oral, start: T+2;N+420
Order Comment:
4 and 8 hours after completion of ifosfamide. To be given in 1 cup of carbonated beverage over 15 minutes. Round dose to nearest 10 mg. Medication is part of a combined IV/PO protocol. Day 3

Versioning: Yes

Jira: CST-161170

PowerPlan: GOTDEMACO

Cycles/PowerPlans: GOTDEMACO outpatient (day 8 only) + GOTDEMACO (inpatient and outpatient)

Changes:

Removed Day 8 pre chemo metrics for neutrophils, platelet count, and creatinine in the outpatient chemotherapy phase of both Powerplans.

ONCP GO GOTDEMACO Outpatient (Day 8 Only) - Cycle 1, Chemotherapy (Day 8) (Future Pending) *Est

	Component	Day 8
		Future Pending
		*Est. 18-Mar-2022 08:...
		Actions ▾
	Link to Protocol: Therapy for High Risk Gestational Trophoblastic Neoplasia (GTN) using Etoposide, Methotrexate, Leucovorin (Folinic Acid), DACTINomycin, Cyclophosphamide and vinCRISine	
	This plan is for outpatient Day 8 treatment only. Patient to receive Day 1 and Day 2 as an inpatient (refer to proto...	
	Pre-Medications	
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm	
<input checked="" type="checkbox"/>	ondansetron	-30 min

Versioning: Yes

Jira: CST-161173

PowerPlan: LYCODOXMR

Cycles/PowerPlans: LYCODOXMR (inpatient)

Changes:

In the IR Scheduling for Intrathecal Chemo phase, an IR lumbar puncture with injection order for Day 19 was added

ONCP LY LYCODOXMR (Inpatient) - Cycle 2, IR Scheduling for Intrathecal Chemo (Initiated Pending)

For Interventional Radiology administration, select the orders below:		
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Reason: Intrathecal chemotherapy administration, Order for future visit Day 3
<input type="checkbox"/>	<input checked="" type="checkbox"/> IR Lumbar Puncture with Injection	Routine, Reason: Intrathecal chemotherapy administration, Order for future visit Day 19
Ensure Intrathecal Chemotherapy orders are completed (see Intrathecal Chemotherapy Phases)		

A new Intrathecal Chemotherapy phase was added for Day 19. Contents are same as Day 3 phase.

ONCP LY LYCODOXMR (Inpatient) - Cycle 2, Intrathecal Chemotherapy. (Day 19) (Future Pending) *Est. 17-Mar-2022 15:38 PDT - 21 Day

		Day 19
		Future Pending
		*Est. 17-Mar-2022 15:38 PDT
		Actions
Pretreatment Labs		
<input checked="" type="checkbox"/>	PTT Blood, Routine, Unit collect, once, Order for future visit	Planned
<input checked="" type="checkbox"/>	INR Blood, Routine, Unit collect, once, Order for future visit	Planned
Pre-Chemo Metrics		
Give cytarabine if no peripheral blasts (acute leukemia) and Platelet Count greater than 50 x 10 ⁹ /L		
INR Less Than 1.5 and PTT Less Than or Equal to ULN		
Treatment Regimen		
Physician may start intrathecal chemotherapy with Cycle 1 if high risk of CNS disease		
Physician may change the days of Intrathecal chemotherapy with a minimum of 48 hours between doses		
A total of 8 doses of IT chemotherapy should be given for all patients undergoing MAGRATH protocol (those with CNS disease may require more than 8 IT doses)		
Therapeutic dalteparin: MD to write separate order for holding therapeutic anticoagulation according to the following guidelines: - Once daily therapeutic, LMWH should be held 36 hours prior to the procedure and resumed the day after the procedure - In patients at high risk of thrombosis (e.g., acute thrombosis, less than 30 days from diagnosis of VTE), MD may consider changing to BID dosing and giving half the therapeutic dose of LMWH at 24 hours prior to the procedure, and resuming the day after the procedure		
<input checked="" type="checkbox"/>	cytarabine (cytarabine - oncology) +4 hr 50 mg, intrathecal, once oncology, drug form: inj Intrathecal Use Only	Planned
Bed rest for 30 minutes after procedure in supine position		
Cerebrospinal Fluid Labs		
<input checked="" type="checkbox"/>	Cell Count CSF (CSF Cell Count and Differen... +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on...	Planned
<input checked="" type="checkbox"/>	Protein CSF (CSF Total Protein) +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on...	Planned
<input checked="" type="checkbox"/>	Glucose CSF +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on...	Planned
<input checked="" type="checkbox"/>	Pathology Non GYN Cytology Request (Path... +4 hr AP Specimen CSF Pathology	Planned
<input checked="" type="checkbox"/>	Immunophenotyping LPD (Immunophenoty... +4 hr Cerebrospinal fluid, Routine, Unit collect, Collection: T;N, on...	Planned
<input type="checkbox"/>	CSF Culture (CSF C&S) +4 hr Cerebrospinal fluid, once, Order for future visit	
Schedulable Orders		
<input type="checkbox"/>	IR Lumbar Puncture with Injection Routine, Reason: Intrathecal chemotherapy administration, ... Day 19	

Versioning: Yes

Jira: CST-161870

PowerPlan: SCNAUSEA

Cycles/PowerPlans: ONCS Post Chemotherapy Antiemetics (SCNAUSEA)

Changes:

Under the section For highly emetogenic agents, added a 2.5mg option for olanzapine.

Component	Status	Details
ONCS Post Chemotherapy Antiemetics (SCNAUSEA) (Future Pending)		
Medications		
Link to Protocol		
Revised: 1 April 2022		
For highly emetogenic agents:		
<input type="checkbox"/>	aprepitant	80 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800 Days 2 and 3
<input type="checkbox"/>	dexamethasone	4 mg, PO, BID, order duration: 2 day, drug form: tab, start: T;1700 Days 1 and 2
<input checked="" type="checkbox"/>	OLANzapine	2.5 mg, PO, qdaily, order duration: 3 doses or times, drug form: tab, start: T+1;0800 Days 2, 3, 4
Do not use OLANzapine with prochlorperazine or metoclopramide		
<input type="checkbox"/>	prochlorperazine	5 mg, PO, qdaily, order duration: 3 doses or times, drug form: tab, start: T+1;0800
<input type="checkbox"/>	metoclopramide	10 mg, PO, qdaily, order duration: 3 doses or times, drug form: tab, start: T+1;0800
For moderately emetogenic agents:		

Under the section For moderately emetogenic agents, added a 2.5mg option for olanzapine.

For moderately emetogenic agents:		
<input type="checkbox"/>	dexamethasone	4 mg, PO, BID, order duration: 2 day, drug form: tab, start: T;1700 Days 1 and 2
<input checked="" type="checkbox"/>	OLANzapine	2.5 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800 Days 2 and 3
Do not use OLANzapine with prochlorperazine or metoclopramide		
<input type="checkbox"/>	prochlorperazine	5 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800
<input type="checkbox"/>	metoclopramide	10 mg, PO, qdaily, order duration: 2 doses or times, drug form: tab, start: T+1;0800
For low emetogenic agents:		

Versioning: Yes

Jira: CST-162587

PowerPlan: GILEN

Cycles/PowerPlans: All associated Regimens and Powerplans

Changes:

Regimen and powerplan description updated to:

“Therapy of Advanced Hepatocellular Carcinoma Using Lenvatinib”

ONC GI GILEN (PO) (Pending)

▼ Hide additional details

Regimen description: Therapy of Advanced Hepatocellular Carcinoma Using Lenvatinib

Versioning: No

Jira: CST-163739

PowerPlan: GISORAF

Cycles/PowerPlans: All associated Regimens and Powerplans

Changes:

Regimen and powerplan description updated to:

“Therapy for Advanced Hepatocellular Carcinoma using SORafenib”

ONC GI GISORAF (PO) (Pending)

▼ Hide additional details

Regimen description: Therapy for Advanced Hepatocellular Carcinoma using SORafenib

Versioning: No

Jira: CST-163738

Jira Ticket #	CST-163739, CST-163738, CST-162587, CST-161870, CST-161173, CST-161171, CST-161170
How-to questions?	http://cst.cernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444